RE:RE:RE:Highlights from Resverlogix Rodman and Renshaw 9/10BDAZ and GV.
I do find this change rather interesting. Did they provide any rationale? Perhaps in the post hoc analysis they found the rvx-208 effect was strongest within this group of 3 MACE conditions? Perhaps the further analysis on the epigenetic effects of rvx-208 has also added to the tighter definition? I hope so because it seems to me that moving from 5 MACE conditions to 3 at face value would reduce the reduce the RRR % numbers unless they have evidence to suggest the 3 picked are the optimal targets. I guess there could be many other factors for this choice such as the size of market and severity and health care impacts of this group.
I'll hope the scientists have a good grip on this.
Hopeful but frustrated by the lack of focus on the business side.
Toinv